{"id":378071,"date":"2023-12-08T19:19:31","date_gmt":"2023-12-09T00:19:31","guid":{"rendered":"https:\/\/platohealth.ai\/bms-dealmaker-mily-to-depart\/"},"modified":"2023-12-10T12:00:22","modified_gmt":"2023-12-10T17:00:22","slug":"bms-dealmaker-mily-to-depart","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/bms-dealmaker-mily-to-depart\/","title":{"rendered":"BMS dealmaker Mily to depart","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

ARTICLE | Management Tracks<\/p>\n

\n
\n
\n

Plus: CCO Olinger leaving Amylyx and updates from Coherus, Compass and NanoMosaic<\/h2>\n

\n By\u00a0Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst<\/span>\n<\/p>\n

December 9, 2023 12:19 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

Bristol Myers Squibb Co.<\/a><\/b> (NYSE:BMY) confi<\/span>rmed that EVP, Strategy and Business Development Eliza<\/span>beth Mily would leave the company, and that it is searching for a successor. Mily worked on several high-profile BMS acquisitions<\/a>, including those of Mirati Therapeutics Inc. (NASDAQ:MRTX), MyoKardia Inc. and\u00a0Turning Point Therapeutics Inc.<\/p>\n

Amylyx Pharmaceuticals Inc.<\/a><\/b> (NASDAQ:AMLX) disc<\/span>losed in an SEC filing the departure of Chief Commercial Officer Margaret Olinger, effective Dec. 31. Amylyx added that it too is searching for a successor…<\/p>\n